SDI INTRODUCES RIVA STAR

SDI (North America), Inc is pleased to announce the U.S. Food and Drug Administration (FDA) has given registration approval to market Riva Star in the USA.

Riva Star’s FDA registration is as a new generation silver diamine fluoride (SDF) desensitizer that immediately relieves tooth sensitivity. SDI Limited has already been successful in registering Riva Star in several key Latin American countries such as Brazil, Peru, and Colombia as an anti-caries agent.

Riva Star’s key ingredients are SDF and potassium iodide (KI). SDF has known antibacterial activity which stops decay in teeth. Combined with the KI, Riva Star has a higher inhibition zone against four bacterial species compared to sodium hypochlorite1.

Unlike any other SDF based system, Riva Star’s two step globally patented procedure minimizes the risk of staining the tooth black. By applying the KI solution over the SDF, a silver iodine precipitate is formed which does not stain teeth as does using other SDF treatments alone. This patented two-step process results in an esthetically acceptable tooth colored appearance for the patient.

Riva Star is essential for clinicians practicing minimally invasive dentistry.2-5 It conditions dentin and may assist in tooth preservation.

Riva Star’s unique capsule system is color-coded and extremely easy to use, saving the clinician and patient precious time. The capsule system also prevents the spillage of SDF normally supplied in bottles, which will stain surfaces black.

Riva Star increases bond strengths of glass ionomer cements. Pre-treating the tooth surface with Riva Star is a great way to enhance bonding of glass ionomers to dentin.6

Riva Star is a revolutionary desensitizing star, a solution and innovation to the dental industry in reducing tooth sensitivity for patients without the negative esthetic effects of other silver diamine fluoride products.

Riva Star is available through all major dental distributors.

For more information, visit sdi.com.au or contact SDI (North America), Inc. at 800-228-5166.

 


REFERENCES

  1. Heo J. Tompkins GR, Love RM.; Evaluation of the Antimicrobial Activity of Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) as an Endodontic Medicament; University of Otago, New Zealand, 2010.
  2. Knight GM, Mclntyre JM, Craig G, Zilm PS, Gully N.; Inability to form a biofilm of Streptococcus mutans on silver fluoride-and potassium iodide-treated demineralized dentin. Quintessence international (Berlin, Germany: 1985) 2009;40:155.
  3. Knight GM.; The Pharmacological management of dentine to protect against plaque microorganism degradation. PhD Thesis University of Adelaide 2008.
  4. Knight GM, Mclntyre JM, Craig G, Zilm PS, Gully NJ.; Differences between normal and demineralized dentine pretreated with silver fluoride and potassium iodide after an in vitro challenge by Streptococcus mutans. Australian Dental Journa l 2007;52:16-21.
  5. Knight GM, Mclntyre J, Craig G.; Ion uptake into demineralized dentine from glass ionomer cement following pretreatment with silver fluoride and potassium iodide. Australian Dental Journal 2006;51 :23 7 -24l.
  6. Knight GM, Mclntyre JM.; The effect of silver fluoride and potassium iodide on the bond strength of auto cure glass ionomer cement to dentine. Australian Dental Journal 2006;51:42-45.

 

Add a Comment

Dave Misiak Joins Young Innovations as Vice President of Sales and Marketing
ORAL HEALTH AMERICA RECEIVES GRANT FROM DENTAQUEST FOUNDATION TO ADVOCATE FOR PUBLICLY FUNDED DENTAL COVERAGE
Glidewell Dental to Present 2nd Annual Educational Symposium Near Washington, D.C.
American Dental Association Announces Promotion of Catherine Mills